CHC – The Cancer & Hematology Centers

PAL-E602-001 (Palleon)

Description:  A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Cancers


Target Patient Population:   Melanoma, Ovarian, Non Small Cell Lung Cancer, Colorectal and Pancreatic cancers

Study Design:  Drug is given IV weekly.